ANTG Inks Deal with Curaleaf to Supply Medical Cannabis for UK Patients

LONDON – Australian Natural Therapeutics Group, a leading cultivator of pharmaceutical-grade Cannabis, has reached an agreement with Curaleaf Laboratories to bring its products to British patients, marking a cross-continental push into Europe’s second-largest medical Cannabis market.

Under the terms, ANTG will export its Australian-grown formulations to Curaleaf’s EU-GMP certified facility in the United Kingdom, where they will undergo final manufacturing, packaging, and distribution for prescription use. The first batches are slated to reach clinicians on the UK Specialist Register as early as this month, channeling the medicines through established pharmacy networks. This setup leverages ANTG’s expertise in stable, research-backed strains with Curaleaf’s on-the-ground infrastructure, aiming to meet rising demand without the delays of long-haul imports.

The partnership arrives at an opportune moment for the UK sector. With more than 60,000 active patients and annual sales projected to top $320 million this year, the market faces pressure from a patient base expected to nearly double by 2028. Domestic production has ramped up since Cannabis-based medicines gained legal footing in 2018, but supply bottlenecks persist, particularly for high-potency, traceable options. ANTG’s entry could ease those strains by injecting volume from a jurisdiction known for stringent cultivation standards; Australia exported over 3 tons of medical Cannabis last year, underscoring its reliability as a source.

“This collaboration pairs two outfits focused on quality and real-world results,” said Matt Cantelo, ANTG’s founder and chief executive. “It’s a clear signal of trust in Australian-sourced cannabinoids, and it puts consistent options in front of UK doctors and their patients.” Richard Hodgson, managing director at Curaleaf Laboratories, echoed the sentiment: “ANTG’s track record in formulation fits our drive to raise the bar on evidence-driven therapies.”

From a broader view, the deal highlights Australia’s ascent as a global exporter, filling gaps left by variable yields in Europe. Yet it also tests whether imported genetics can scale affordably against local rivals [Curaleaf’s facility already handles multiple brands], so integration risks are low, but pricing will matter as reimbursement talks heat up. For investors eyeing consolidation, this signals steady, if unspectacular, growth [UK prescriptions climb 25% year-over-year] in a regulated space where compliance trumps hype.